Clinical Characteristics No. of Patients (%) No. of Patients (%)
neoadjuvant treatment group (n=9) adjuvant treatment group (n=16)
Gender
Male 6 (66.7) 6 (37.5)
Female 3 (33.3) 10(62.5)
Age:Median [range], y 57[34-67] 58[42-72]
Weight: Median [range], kg 67[52-90] 61.5[45-85]
Height:Median[range],cm 168[152-177] 165[150-178]
Primary site
Stomach 7(77.8) 11(68.8)
Small intestine 2(22.2) 5(31.2)
Kinase mutation
c-kit 11 mutation 7(77.8) 10(62.5)
c-kit 9 mutation - 1(6.3)
unknown 2(22.2) 5(31.2)
Dosage
200 mg/d - 1(6.3)
300 mg/d - 4(25.0)
400 mg/d 9(100) 9(56.2)
600 mg/d - 2(12.5)
Medication duration:Median[range],d 110[30-300] 39[8-420]